Compare BioNano Genomics Inc (BNGO) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs M&T Bank Corporation — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while M&T Bank Corporation trades at $252.63 (market cap $36.42B). The key difference: M&T Bank Corporation is far larger — about 2666.2× BioNano Genomics Inc's market cap, and M&T Bank Corporation pays a 2.38% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MTB | |
|---|---|---|
Market Cap | $13.66M | $36.42B |
Sector | Health | Financials |
52-Week High | $4.92 | $254.04 |
52-Week Low | $1.06 | $178.63 |
Enterprise Value | $16.26M | — |
Dividend Yield | — | 2.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
M&T Bank (MTB) trades at $251.13, up 0.27% on the day, with a bullish technical signal and strong recent earnings beats. The stock shows consistent revenue growth, with 2025 revenue at $9.63B and net income margin of 29.59%, supported by a P/E of 13.35. Analyst consensus is a Hold with a $255.92 price target, while recent news highlights robust Q2 2026 results and dividend stability.
Outlook remains positive due to earnings momentum and loan growth, but risks include rising costs and macroeconomic pressures. The stock offers value with a reasonable valuation and dividend yield, though investor caution is warranted amid mixed analyst ratings and net cash flow challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
